Business Wire

GlobalLogic OTT Service Offerings for Streaming Platforms Proven to Significantly Reduce Go-to-Market Timelines

Share

GlobalLogic Inc., a Hitachi Group Company and leader in Digital Engineering, today announced availability of technology accelerators that significantly reduce time to market of custom Over-The-Top (OTT) applications by as much as 30 to 50 percent. This is accomplished through the development of advanced solution accelerators for application development and testing across all major mainstream OTT platforms. GlobalLogic delivers this capability through a software engineering team with deep expertise in the end-to-end OTT value chain, which has developed more than 200 complex applications over the past ten years as part of multiple global OTT services rollouts.

OTT Digital Accelerators

The world of streaming applications has become immense and complex. Consumers demand high-quality, immersive viewing experiences from any provider on any device. To satisfy this demand and increase consumer engagement, OTT service providers must develop extremely efficient, native application experiences across multiple platforms, including living room (Smart TV, Streaming Device), mobile, web and gaming environments. Streaming applications must be highly reliable and resilient, to assure content will be available 24/7. And systems must be robust to enable providers to monetize the service. Global rollouts add additional complexity to the entire development process.

Over the last ten years, GlobalLogic has been delivering custom OTT platform application development services for more than 20 streaming platform customers—resulting in the creation of best practice frameworks and accelerators for faster development of OTT services. The GlobalLogic OTT Channel Development Accelerator and TestLab are two such accelerators enabling GlobalLogic customers such as media companies to create exceptionally reliable, immersive experiences for consumers.

The accelerators are platform-agnostic—compatible with the most commonly used consumer streaming services—as well as device-agnostic, supporting gaming consoles, set-top boxes, smartphones, PCs, and tablets. They also support management of multiple devices from a single interface.

OTT Channel Development Accelerator : A customizable media platform that enables the creation of a fully functional, completely branded OTT channel or app from idea to launch-ready in just 2.5 months.1

Key Features and Benefits:

  • Common code base for native applications on similar platforms
  • Support for all VOD models (AVOD, SVOD, TVOD)
  • Advanced, customizable UI/UX features such as unlimited screens or background video
  • Versatile monetization options such as in-app purchases, subscription billing, or ad-based services
  • Code base owned by client with flexible GlobalLogic engagement models

OTT TestLab Accelerator : A unified infrastructure that schedules automated quality assurance tests on all OTT devices. Clients can test on their own devices, or leverage GlobalLogic’s devices and labs. This is further enhanced by custom, automated test cases for all major platforms and use cases.

Key Features and Benefits:

  • Makes testing possible as soon as channel development project begins
  • Jump starts continuous integration/continuous delivery (CI/CD) pipelines
  • Simple KPI set up and viewing with easy app adjustment capabilities based on results
  • Eliminates need to purchase duplicate equipment dedicated to each device
  • 3,000+ test devices spanning all major platforms, vendors, use-cases

“The OTT application landscape has grown dramatically larger and more complex over the past few years, and our clients are seeking partners to help navigate it,” said Arun Mukunda, VP and Global Head, Media and Entertainment, GlobalLogic. “Having delivered hundreds of complex OTT applications, GlobalLogic is in a unique position to help our clients rapidly create and launch high quality streaming services on a global scale at a pace never before possible.”

About GlobalLogic

GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.

GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.


1 Approximate time frame based on building and launching a standard app. More complex apps may take longer.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

GlobalLogic, Inc. (Global)
Heather Ailara
211 Communications
+1.973.567.6040
heather@211comms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye